Spacelabs Healthcare receives FDA marketing clearance for new compact monitor

OSI Systems, Inc. (NASDAQ: OSIS), a vertically-integrated provider of specialized electronic products for critical applications in the Security and Healthcare industries, today announced that its Healthcare division, Spacelabs Healthcare, has received clearance under Section 510(k) from the U.S. Food and Drug Administration to market qube™, a new compact monitor. Small and lightweight - with a long life battery - qube offers portability, accessibility and heightened connectivity - perfect for emergency, general/step-down, and post-anesthesia care units. Caregivers can access current, critical patient information, from bedside throughout transport, to provide the ultimate level of patient care.

“qube™ is designed to create a patient-friendly experience and offer the healthcare provider full functionality, accessibility and device portability, thereby significantly enhancing patient care throughout the hospital environments”

"qube™ is designed to create a patient-friendly experience and offer the healthcare provider full functionality, accessibility and device portability, thereby significantly enhancing patient care throughout the hospital environments," said Deepak Chopra, OSI Systems CEO.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

Sign in to keep reading

We're committed to providing free access to quality science. By registering and providing insight into your preferences you're joining a community of over 1m science interested individuals and help us to provide you with insightful content whilst keeping our service free.

or

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
ARB drugs lead to better blood pressure treatment adherence